Two phase 2 clinical trials showing its efficacy in helping with hostility, somatization (the physical expression of psychological distress), and interpersonal sensitivity (heightened awareness of others' perceptions and reactions) led to University of Toronto researchers to call for a broader reframing of psilocybin-based treatments.
In a new Nature Mental Health scientific paper, they suggest calling psilocybin an "anti-distressant."